Auger Electron Therapy Enhanced by Heat-Triggered Release of I-125-Labeled DNA-Targeted Compounds within the Tumor Microenvironment
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.6c00443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Masayuki Munekane und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa920-1192, Japan. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Doxorubicin, Tumor Microenvironment, DNA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Uehara Memorial Foundation, Shibuya Science Culture and Sports Foundation, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
In Auger electron therapy, the effective delivery of Auger electron-emitting radionuclides to the nuclei of cancer cells is essential for achieving high therapeutic efficacy. In this study, we developed a novel strategy that combined thermosensitive liposomes (TSLs) encapsulating 125I-labeled DNA-targeted compounds. This approach enabled enhanced tumor accumulation via TSL-mediated delivery and efficient nuclear translocation of radioactivity by releasing an 125I-labeled doxorubicin derivative ([125I]I-DOX) within the tumor microenvironment. [125I]I-DOX exhibited high cellular and nuclear uptake, producing potent cytotoxicity through Auger electrons emitted from 125I. [125I]I-DOX-loaded TSLs efficiently released [125I]I-DOX at 43 °C, enhancing its cellular uptake by Colon-26 cells. Tumor accumulation of radioactivity in the heating group was much higher than in the nonheating group, and the accumulation was maintained for up to 48 h postinjection. Intravenous injection of [125I]I-DOX-loaded TSLs (5.0 MBq) and localized tumor heating significantly inhibited tumor growth without body weight loss. The combination of [125I]I-DOX-loaded TSLs and hyperthermia represents a promising strategy for Auger electron therapy targeting the nuclei of cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa920-1192, Japan.
ORCID-Profile: Kenji Mishiro, Takeshi Fuchigami, Kazuma Ogawa
Förderung
- Uehara Memorial Foundation
- Shibuya Science Culture and Sports Foundation
- Japan Society for the Promotion of Science
- Inamori Foundation
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering
- Society of Iodine Science
- Hokkoku Cancer Foundation
Zitieren
APA
Munekane, M., Matsunaga, K., Ozaki, M., Echigo, H., Mishiro, K., Fuchigami, T., & Ogawa, K. (2026). Auger Electron Therapy Enhanced by Heat-Triggered Release of I-125-Labeled DNA-Targeted Compounds within the Tumor Microenvironment. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00443
Vancouver
Munekane M, Matsunaga K, Ozaki M, Echigo H, Mishiro K, Fuchigami T, et al. Auger Electron Therapy Enhanced by Heat-Triggered Release of I-125-Labeled DNA-Targeted Compounds within the Tumor Microenvironment. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00443
BibTeX
@article{Munekane2026,
author = {Munekane, Masayuki and Matsunaga, Kazuki and Ozaki, Miki and Echigo, Hiroaki and Mishiro, Kenji and Fuchigami, Takeshi and Ogawa, Kazuma},
title = {Auger Electron Therapy Enhanced by Heat-Triggered Release of I-125-Labeled DNA-Targeted Compounds within the Tumor Microenvironment},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00443}
}
EUVIMED